Sector
Expertise

Life
Sciences

Life Sciences pharmaceuticals, biotechnology, consumer health, diagnostics, digital health, robotics and medical devices

We are skilled at finding senior executives and experts, renowned scientists, clinicians and researchers worldwide, and assessing them from both a leadership and scientific perspective.

Whether you are a start-up, an established corporation, or a CDMO, working on pre-clinical or clinical development, or commercialisation, we’ll help you build collaborative teams. We are skilled in customising our approach to attract diverse, globally-experienced leaders for science-driven environments.

Graphic

Key Trends in Life Sciences

Diversity and Sustainability

Global patient demographics, emerging market demands and opportunities, and an increasingly female talent pool require inclusive leadership. Business leaders must become adept at recognising and prioritising the importance of diversity to harness its advantages for business and society.

When it comes to sustainability, we aspire to the same standards as our clients. We are proud to have been awarded a Bronze rating by Ecovadis in 2022.

1

Collaboration

New business models require collaborative approaches to pipeline innovation, manufacturing and supply, and myriad bench-to-bedside translations. This matrix of layered initiatives requires leaders at all levels of the organisation to be capable of cutting across traditional disciplines through influence, persuasion and compromise.

2

Precision and Personalised Medicine

The scientific advances that are giving rise to precision and personalised medicine are some of the great disruptors of our time. The radical changes that will emerge require leaders to be highly flexible, broad thinkers, who are comfortable challenging and ultimately dismantling the status quo.

3

Value-Driven Patient Access in a Limited Resource Healthcare Ecosystem

Long-term strategic planners who can realistically assess risk and make tough R&D decisions are needed to lead life science companies. They must provide value-driven access to a wide variety of customers and stakeholders in a healthcare ecosystem with limited resources, as well as develop innovative products and therapies. Alternative channels to market will be an inevitable component of any new strategy.

4

Diversity and Sustainability

Global patient demographics, emerging market demands and opportunities, and an increasingly female talent pool require inclusive leadership. Business leaders must become adept at recognising and prioritising the importance of diversity to harness its advantages for business and society.

When it comes to sustainability, we aspire to the same standards as our clients. We are proud to have been awarded a Bronze rating by Ecovadis in 2022.

5

Big Data, Digitalization, and Artificial Intelligence

Big data collection and usage; digitalization; and artificial intelligence in the entire life-cycle of therapies, from development to the point of patient access, are unstoppable trends. Wielding these technology tools in a meaningful way requires innovation leadership that is balanced by well-defined change management skills and a keen ability to prioritise.

Latest News in Life Sciences

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

Subscribe to our Weekly Newsletter

Understanding your business is our business

How can we help you?

We're easy to reach